Medicine and Dentistry
Malignant Neoplasm
100%
Transplantation
92%
Hematopoietic Stem Cell
73%
COVID-19
63%
Oncology
53%
Adolescent
52%
Cell Transplantation
41%
Acute Lymphoblastic Leukemia
41%
Pediatrics
31%
Quality of Life
31%
Non-Hodgkin Lymphoma
26%
Infection
25%
Testis Cancer
24%
Hematologic Malignancy
23%
Hematopoietic Stem Cell Transplantation
23%
Acute Myeloid Leukemia
23%
Cancer in Young Adults
21%
Disease
20%
Survivorship in Cancer Care
20%
Hematopoietic Stem Cell
19%
Breast Cancer
18%
Allotransplantation
18%
Odds Ratio
17%
Chimeric Antigen Receptor T-Cell Immunotherapy
16%
Overall Survival
16%
Fertility Preservation
15%
Hodgkin's Lymphoma
15%
Reproductive Public Health
15%
Minimal Residual Disease
13%
Peripheral Blood Stem Cell
13%
Female Genital Tract Cancer
13%
Late Effect
13%
Lymphoblastic Lymphoma
12%
Chimeric Antigen Receptor T-Cell
12%
Health Care
11%
Immunotherapy
11%
Multiple Myeloma
11%
B Cell
11%
Severe Acute Respiratory Syndrome Coronavirus 2
10%
Immunosuppressive Treatment
9%
Reduced Intensity Conditioning
9%
Myelodysplastic Syndrome
9%
Patient Referral
9%
Intensive Care Unit
9%
Allogeneic Hematopoietic Stem Cell Transplantation
9%
Conditioning
9%
Depression
9%
Childhood Cancer
9%
Clinical Trial
9%
Engraftment
9%
Keyphrases
Older Adults
60%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
51%
COVID-19
48%
Acute Lymphoblastic Leukemia
29%
Young Adult Oncology
28%
Patients with Cancer
27%
Adult Cancer
24%
Acute Myeloid Leukemia
23%
Improved Outcomes
23%
Young Cancer Patients
19%
Non-Hodgkin Lymphoma
19%
Hematopoietic Cell Transplantation
18%
Hematopoietic Cell Transplant
17%
Young Adult Patients
16%
Relapsed Lymphoma
15%
Young Adult Cancer Survivors
15%
COVID-19 Inpatients
15%
Chimeric Antigen Receptor T Cells (CAR-T)
15%
COVID-19 Severity
15%
Conditioning Regimen
12%
Clinical Trials
12%
Confidence Interval
12%
United States
12%
High Risk
11%
Oncology Patients
11%
Minimal Residual Disease
11%
Allogeneic Transplantation
11%
Chimeric Antigen Receptor T-cell Therapy
11%
Overall Survival
11%
Oregon
11%
Pediatric
11%
Infertility
11%
Oncology
10%
Transplant Outcomes
9%
Hematological Malignancies
9%
Posttraumatic Stress Symptoms
9%
Fertility Preservation
9%
Retrospective Cohort Study
9%
National Cancer Institute
9%
Progress Review
9%
Marrow Transplantation
9%
Sarcoma
9%
Breast Cancer
9%
Late Effects
9%
Registry-based
9%
Pediatric Oncology
8%
Healthcare Professionals
8%
T Cell Receptor
8%
Testicular Cancer
8%
Haematopoietic Stem Cell Transplant Recipients
8%